Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06153446 · ClinicalTrials.gov registry record
Infection Consortium Study#1
A clinical trial, sponsored by Zimmer Biomet.
- Completed
- Registry status
- 810
- Enrollment target
NCT06153446: Completed study, sponsored by Zimmer Biomet.
NCT06153446 is a clinical trial that has completed, run by Zimmer Biomet. The registered enrollment target is 810 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06153446 has completed, sponsored by Zimmer Biomet.
- COMPLETED
- Registry status
- 810 participants
- Enrollment target
Study Summary
In this study, the Sponsor wants to evaluate the performance and accuracy of the PJI Panel compared to the currently used multiple-criterion scoring systems for the diagnosis of PJI.
Primary Outcome
The primary endpoint of this study is the rate of agreement (positive and negative) for the diagnosis of PJI between the PJI Panel and the previous and current clinical guidelines.
Interventions
- DIAGNOSTIC_TEST Synovasure® Comprehensive Infection Panel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 810 participants |
| Start Date | 2023-12-10 |
| Est. Completion | 2025-09-04 |
What the finished NCT06153446 record still lists
NCT06153446 is an observational study that tracks outcomes without assigning an intervention. The registered 810 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Synovasure® Comprehensive Infection Panel is the first listed.
NCT06153446 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06153446 about?
NCT06153446 is a clinical study titled "Infection Consortium Study#1". In this study, the Sponsor wants to evaluate the performance and accuracy of the PJI Panel compared to the currently used multiple-criterion scoring systems for the diagnosis of PJI.
What is the current status of trial NCT06153446?
This trial is currently completed. The enrollment target is 810 participants. The study started on 2023-12-10. Estimated completion is 2025-09-04.
What interventions are being tested in trial NCT06153446?
The interventions under investigation include: Synovasure® Comprehensive Infection Panel (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06153446?
This trial is sponsored by Zimmer Biomet, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519085 · 810 participants · Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- NCT06065098 · 806 participants · NA
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI